Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cat eye syndrome chromosome region, candidate 3 (CECR3) is a long non-coding RNA (lncRNA) gene located on human chromosome 22q11.1, identified as part of the critical region duplicated or triplicated in Cat eye syndrome (CES)[3][5]. Although CECR3 is robustly expressed in certain tissues, its direct function and specific involvement in human disease have not been defined beyond its association with Cat eye syndrome due to chromosomal abnormality[1][3]. There is no evidence that CECR3 acts as a protein, receptor, drug target, or has a direct therapeutic role. CECR3 is one of several candidate loci mapped to the Cat eye syndrome critical region, identified largely through comparative sequence analysis with mouse DNA, but currently has no established biological function, molecular interactions, or use as a biomarker[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cat eye syndrome chromosome region, candidate 3 (non-protein coding) (CECR3).